## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($301.74)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Who Owns Amgen? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20251209T130753 | Bullish | Relevance: 100%
-  This article details the top shareholders of Amgen Inc. (NASDAQ: AMGN), primarily large institutional investors and passive funds, alongside recent adjustments by active managers and hedge funds. It also reviews recent insider trading activity, noting that sales were modest and purchases by directors appeared administrative, suggesting a neutral stance on near-term performance. The overall sentiment indicates strong long-term confidence in Amgen's cash flow durability and pipeline potential.

**2. Amgen (NASDAQ: AMGN) declares $2.52 Q1 2026 dividend, record Feb. 13, pays Mar. 6**
- Source: Stock Titan | 20251209T210246 | Bullish | Relevance: 99%
-  Amgen (NASDAQ: AMGN) has declared a quarterly dividend of $2.52 per share for the first quarter of 2026. The dividend was announced by the Board of Directors on December 9, 2025, with a record date of February 13, 2026, and a payment date of March 6, 2026. All stockholders recorded as of the close of business on the record date will be eligible for this dividend.

**3. Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc.**
- Source: MarketBeat | 20251209T103052 | Somewhat-Bullish | Relevance: 99%
-  Daiwa Securities Group Inc. has increased its holdings in Amgen Inc. by 5.1% in the second quarter, bringing its total ownership to 229,666 shares valued at $64.125 million. Several other hedge funds also adjusted their stakes in Amgen, while some corporate insiders sold shares. Wall Street analysts have issued mixed ratings for Amgen, with a consensus "Moderate Buy" and an average target price of $335.65.

**4. Amgen (NASDAQ:AMGN) gets FDA OK for Uplizna as first CD19 B-cell therapy for gMG**
- Source: Stock Titan | 20251211T231111 | Bullish | Relevance: 99%
-  Amgen (NASDAQ:AMGN) announced FDA approval of UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-AChR and anti-MuSK antibody positive. This approval is based on data from the Phase 3 MINT trial, demonstrating significant symptom control and marking UPLIZNA as the first CD19-targeted B-cell therapy for these gMG subtypes, with a convenient twice-yearly maintenance dosing schedule. UPLIZNA already has two previous FDA approvals for NMOSD and IgG4-RD, establishing it as a multi-indication therapy.

**5. Jump Financial LLC Acquires 21,920 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251210T120752 | Somewhat-Bullish | Relevance: 98%
-  Jump Financial LLC significantly increased its stake in Amgen Inc. by 1,449.7%, acquiring an additional 21,920 shares, bringing its total holdings to 23,432 shares valued at $6.542 million. This comes as Amgen reported strong quarterly earnings, beating analyst estimates, and increased its quarterly dividend. The company currently holds a "Moderate Buy" rating from analysts with an average price target of $335.65.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Forward P/E 14.5x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (3 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $170.9B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 14.5 |
| Current P/E | 14.9 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -4.3% to -7.2% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.2pp (needs >4.0% for momentum thesis). AM_20 at -5.1% indicates price below own 20MA trend. Underperforming sector by 4.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-4.59), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.18% (CS: 5) | Weak |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | -4.59 | Bearish |
| vs SMA20 | 0.948x | Below |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.069x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $317.38
- **Stop Loss:** $301.74 (4.9% risk)
- **Target:** $348.66 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $27,929.44
- **Portfolio %:** 27.93%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*